According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

A court-appointed special master recommended a bid backed by Gold Reserve and Koch over a rival hedge-fund offer. Krispy Kreme's top finance executive, Jeremiah Ashukian, is leaving the doughnut maker ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

The actor is raising awareness of clinical trials for cancer in partnership with “GMA” sponsor Eli Lilly & Co.

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

Neurizon enters global licensing agreement with ElancoNeurizon Therapeutics (ASX:NUZ) has signed an exclusive global ...